Friday | February 4th, 2022
CEO MESSAGE
Today is the International Day of Women and Girls in Science, a UN global observation since 2015  that seeks to raise profile for full and equal access and participation. Although there is approaching parity in life sciences (based on numbers), other sectors lag, and the research pipeline generally still shows bias.  

Increasing diversity leads to increased benefits in many key areas. We’re including sessions about this in next week’s Access to Innovation, including diversity in and decentralization of clinical trials. For an illustration on why this is important, check out this week’s Fierce Pharma article on enrolling more black women in breast cancer clinical trials Increasing the diversity of participants here should mean that more of the drugs used in treatment actually work for this demographic. 

Our former CEO and President, Karimah Es Sabar also touches on one of the themes of Access to Innovation – data. As a member of the Industry Strategy Council and past chair of the health and biosciences economic strategy table, and current general partner of LSBC member, Quark Venture she’s quoted in this Globe and Mail article. “And [the Canadian government] should invest in ‘world-leading digital infrastructure’ that enables researchers to harness vast troves of medical data marooned in disparate databases across Canada to help develop ground-breaking medicines. It is important that we take our single biggest investment – health care – and turn it into an economic engine.”  

Day 2 of our conference covers data, data handling, and streamlining data acquisition from bedside to bench – Building Hospitals of the Future. Industry experts from Compugen, Deloitte and Providence Health will share their insights. This along with sessions on IP, the road to commercialization and how mRNA will save the world are pretty good reasons for registering – see you next week, February 16 and 17. Register here.

Karimah’s insights also touch on how Canada needs a 10- to 20-year strategic plan for investment and financial support in health and biosciences; there needs to be an economic development mandate alongside streamlining regulations that make it easier for innovative products to reach the market.  

…innovative products such as universal donor blood. Karimah is also featured in The Hill Times this week, talking about glycomics and the Glyconet report. Mentioning LSBC member, ABOzymes, she notes that Canada has been at the forefront of glycomics research for many decades, and that this particular -omics area is poised as the next frontier in bioinnovation.

As an introduction to ABOzymes, their first product is an additive for a standard blood bag that first primes and then eliminates a [glycan] marker on the red blood cell (RBC) that determines blood group A rendering it group O – universal donor blood. 

Celebrating innovation is one of the best parts of Life Sciences BC; congratulations to our global pharma member and sponsor, Pfizer for reaching number 4 in Fortune’s World’s Most Admired Companies list  and to Vancouver Coastal Health Research Institute, on their CIHR project grants awards. And welcome to Monique Henson, joining the Smart and Biggar patents team in Vancouver.

I was thrilled to see the Life Sciences sector called out in the Throne Speech delivered this week. Under the heading of Building a stronger economy – for everyone, life sciences was cited as an example. Specifically “B.C. companies are helping to solve major challenges around the world, while attracting talent and investment to our province. Last year, B.C. experienced a surge in private technology startups valued at more than $1 billion. In fact, 2021 was one of the best years ever for raising capital by B.C. companies.”  

There was a hint of what might be included in the upcoming economic vision, which was described as “grow(ing) the economy with purpose” with the goal of having economic growth that is inclusive and sustainable by creating the “high-skill, low-carbon economy of tomorrow”. It noted that forecasted labour shortages and skill gaps will need to be addressed, and said the new forthcoming Economic Plan (scheduled to be released next week) will include a generational commitment to develop the talent B.C. needs to close the skills gap.

Wendy and the LSBC Team
Please visit our Flood and Landslide Relief Program page to learn about this and other initiatives
PLATINUM SPONSORS
Canadian CRO IonsGate Preclinical Services Inc (IonsGate), that is a market leader in preclinical research services, and European life sciences company InSilicoTrials just announced a partnership to leverage innovative technology like Modeling and Simulation....Read More
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that management will participate in upcoming investor conferences....Read More
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that a total of approximately 3.1 million courses of molnupiravir, an investigational oral antiviral COVID-19 medicine, have been provided to the U.S. government for allocation across the country....Read More
Zucara Therapeutics Inc. announced that the peer-reviewed journal, Diabetes, Obesity and Metabolism, has published a paper reporting positive preclinical data showing the effect and pharmacokinetics of ZT-01, which is currently in a Phase 1b proof-of-concept trial for the treatment of insulin-induced hypoglycemia in patients with Type 1 diabetes....Read More
Ondine Biomedical Inc. has treated the first patients in its nasal photodisinfection exploratory Phase 2 trial. The study will evaluate how effectively the treatment eradicates pathogens – Staphylococcus aureus – in the nose, and the occurrence of surgical site infections within 30 days of surgery....Read More
The U.S. Food and Drug Administration has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease. Enjaymo is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells....Read More
Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced it has completed enrollment in its Phase 2 NP-120 idiopathic pulmonary fibrosis and chronic cough study....Read More
Gandeeva Therapeutics, a Vancouver-based company led by UBC Faculty of Medicine professor Dr. Sriram Subramaniam, recently announced that it raised US$40 million in Series A funding to advance the development of new drug treatments....Read More
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that management will report its fourth quarter and full year 2021 financial results after market close....Read More
Positive results from long-term, open-label extension studies demonstrated that olipudase alfa provided sustained improvement in lung function and reduction of spleen and liver volumes in adult and pediatric patients with non-central nervous system manifestations of acid sphingomyelinase deficiency....Read More
BayMedica’s VP of Commercial Operations, Chris Meiering, joins Shadd Dales of The Dales Report to talk about the growth opportunities in the cannabinoid industry. In the interview, Chris talks about how the cannabinoids industry is maturing and the big changes he expects to see in the market. ....Read More
Researchers at the University of British Columbia are shedding new light on the molecular factors that give COVID-19 variants a competitive edge – essential knowledge that could improve disease management as new variants continue to emerge....Read More
Canadian pharmaceutical company SaNOtize Research & Development Corp. and Glenmark Pharmaceuticals Limited, announced successful results of Phase 3 clinical trials and approval from India’s drug regulator for the treatment of adult patients with COVID-19 who have a risk of progression of the disease. ....Read More
BIOTECanada announced the launch of Bio+ech Connec+, a unique forum for early-stage Canadian biotech companies to connect directly with the business development and investment leaders of multinational pharma/biotech companies... READ MORE
BioTalent Canada’s Catalyst Award is an employee recognition award, granting a $1,000 prize to the young employee who has contributed most significantly to their Canadian biotechnology in 2021... READ MORE
GOLD SPONSORS
Brigene Biosciences Inc. is a rapidly growing company that strives to be a leading manufacturer of viral vectors. They are fully integrated service Cell & Gene Therapy CDMOs, provides research grade production, GMP and GMP-S plasmid, GMP viral production.



Visit Website
PHEMI Health DataLab is a unique, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.


SILVER SPONSORS
Project Manager

Evonik is seeking a Project Manager who will create and manage plans utilizing project management tools based on project goals as stated in the technical proposal and input from business development.

Senior Administrator, IT Systems

Notch Therapeutics is seeking a Senior Administrator, IT Systems who will provide technical administrative and design services for all Notch IT systems, whether on-premise or cloud-based. 




LSBC Job Board

Jobs posted to our Job Board automatically post out to all our social media accounts for wider sharing. Make sure you include your company name in the first line of your job ad for maximum exposure!

BRONZE SPONSORS
Post A Job on the LSBC Website!
LSBC Membership Discounts on Job Postings
 
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five reposts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact Peter McLoughlin - talent@lifesciencesbc.ca